In this episode of MD Newsline, Dr. Andreas Hochhaus, Professor of Internal Medicine, Hematology, and Oncology at the Comprehensive Cancer Center in Jena, Germany, shares his expertise on the evolution of chronic myeloid leukemia (CML) therapies. He reflects on decades of progress in CML treatment, from interferon to targeted TKIs, and highlights the importance of tolerability, patient-centered care, and innovative trial data shaping the future of CML management.

Episode Highlights:

The Evolution of CML Therapy

Dr. Hochhaus outlines the transformation of CML treatment, from interferon to imatinib, and the development of second- and third-generation TKIs. He emphasizes advances in efficacy while acknowledging the persistent challenge of drug resistance.

Managing Tolerability and Side Effects

Toxicities such as cardiovascular, hepatic, and renal complications remain key concerns. Dr. Hochhaus discusses how improving tolerability is central to optimizing patient quality of life.

Enliven-01 Trial

He highlights the unique pharmacologic profile of Enliven-01, with fewer off-target effects and encouraging safety data, underscoring its potential as a novel therapeutic option.

ASCIMINIB as a New Standard Comparing

ASCIMINIB with nilotinib, Dr. Hochhaus explains its superior tolerability and efficacy, positioning it as a game-changer in frontline CML therapy.

Patient-Centered Care and Future Directions

Dr. Hochhaus stresses the importance of shared decision-making, molecular monitoring, and pathways to treatment-free remission, while also pointing to challenges such as additional gene mutations and resistance mechanisms.

Key Takeaway:

The future of CML treatment lies in balancing efficacy, safety, and patient quality of life. With emerging therapies like Enliven-01 and ASCIMINIB, clinicians can provide more personalized and effective care while expanding opportunities for treatment-free remission.

Resources:

Website: https://mdnewsline.com/
Newsletter: https://mdnewsline.com/subscribe/
Connect with Dr. Andreas Hochhaus LinkedIn

In this episode of MD Newsline, Dr. Eleonora Teplinksy, a breast and gynecologic medical oncologist at Valley Health System and clinical assistant professor at the Icahn School of Medicine at Mount Sinai, shares key updates from the ASCO annual meeting. She discusses transformative clinical trials that are reshaping the landscape of metastatic breast cancer treatment across subtypes including hormone receptor-positive, HER2-positive, and triple-negative breast cancer.

Dr. Teplinksy highlights the promise of early mutation detection, the potential of antibody-drug conjugates, and the power of liquid biopsies. She also addresses pressing concerns around clinical trial diversity, treatment access, and the need for multidisciplinary care.

Episode Highlights:

Early Detection in HR+ Breast Cancer:

The SERENA-6 Trial The SERENA-6 trial investigates whether switching to camizestrant—an oral SERD—upon early ESR1 mutation detection via liquid biopsy (before radiographic progression) improves progression-free survival. The study showed a 56% reduction in disease progression risk. However, issues around FDA approval, cost, testing frequency, and racial representation remain key concerns.

Advancing Triple-Negative Breast Cancer Care:

ASCENT-04 The ASCENT-04 trial evaluates sacituzumab govitecan plus pembrolizumab vs. standard chemo-immunotherapy in PD-L1+ patients. Results revealed improved PFS (7.8 to 11.2 months), showing promise for first-line triple-negative treatment, though insurance coverage may delay clinical implementation.

HER2+ Breast Cancer Innovation:

DESTINY-Breast09 This trial demonstrated that combining T-DXd with pertuzumab improved PFS from 26.9 to 40 months, suggesting a new standard for HER2+ metastatic breast cancer. Still, side effects like interstitial lung disease and lack of clarity on endocrine therapy integration must be addressed.

Real-World Barriers:

Cost, Toxicity, and Care Access Dr. Teplinksy emphasizes challenges patients face—from time toxicity to insurance denials—and calls for thoughtful side-effect management and patient-centered treatment planning.

Multidisciplinary Collaboration and Future of AI in Oncology

She underlines the role of interdisciplinary care and the need to bridge gaps across specialties. With AI and machine learning emerging, Dr. Teplinksy envisions more tailored treatments driven by biomarkers and real-world insights.

Key Takeaway:

Dr. Teplinksy stresses the importance of early intervention, clinical trial equity, and multidisciplinary care in improving breast cancer outcomes. As the field embraces antibody-drug conjugates and AI-driven personalization, collaboration and access must evolve in step.

Resources:

Website: https://mdnewsline.com/
Newsletter: https://mdnewsline.com/subscribe/
Connect with Dr. Eleonora Teplinksy: Here

In this episode of MD Newsline, Dr. Ashley Sumrall, a neuro-oncologist and Section Chief at Atrium Health Levine Cancer Institute, shares groundbreaking insights into the treatment of diffuse midline gliomas with the H3K27M mutation. Dr. Sumrall presents data from pediatric and adult studies using Dordaviprone (ONC201), highlighting its promising response rates and tolerability. She also discusses the evolving role of AI in neuro-oncology, the value of multidisciplinary care, and the need for advocacy in biomarker access and healthcare policy.

Episode Highlights:

Advancements in Treating Rare Brain Tumors

Dr. Sumrall introduces updated clinical findings on Dordaviprone for diffuse midline gliomas, a rare and aggressive brain tumor affecting children and young adults. The combined adult and pediatric studies showed a 20% overall response rate and minimal serious side effects, offering a new sense of hope in an area with limited treatment options.

Pediatric-Adult Trial Integration

She explains the rationale for combining data from adult and pediatric studies due to the rarity of the disease and evolving definitions of pediatric age groups. This integrated approach offers valuable insights into treatment effectiveness across the age spectrum.

Promise of AI in Neuro-Oncology

Dr. Sumrall emphasizes how machine learning and AI tools like OpenEvidence and ChatGPT can streamline imaging analysis, assist in clinical trial design, and improve diagnostic efficiency. She foresees AI as a co-pilot in tumor boards and day-to-day clinical decisions.

Well-Tolerated Therapy and Quality of Life

Unlike many cancer treatments, ONC201 demonstrates a low side effect profile, with zero serious adverse events reported. This is especially significant for brain tumor patients who often face limited options beyond surgery and radiation.

Biomarkers and Access Challenges

She highlights the importance of biomarker testing in classifying tumors and guiding therapy. However, she warns of ongoing disparities in access due to high costs and limited insurance coverage, particularly in community care settings.

Advocacy for Research Funding and Access

Dr. Sumrall underscores the role of physician and patient advocacy in preserving NIH and NCI funding, expanding access to biomarker profiling, and supporting legislation to streamline patient care.

Collaborative Oncology Models

She describes her work in multidisciplinary tumor boards and genetic predisposition clinics, where oncologists, geneticists, and endocrinologists jointly tailor proactive care plans—an approach she believes should be the gold standard in oncology.

Key Takeaway:

Dr. Sumrall reinforces that innovation in rare brain tumor treatment must be matched by advocacy, access to biomarker testing, and the adoption of AI-powered tools. The progress with ONC201 offers hope not just in extending life but also in improving the quality of life for patients once left without options.

Resources:

Website: https://mdnewsline.com/
Newsletter: https://mdnewsline.com/subscribe/
Connect with Dr. Ashley Sumrall: Here

In this episode of MD Newsline, Dr. Karine Tawagi, a genitourinary medical oncologist at the University of Illinois in Chicago, shares cutting-edge updates from ASCO 2024 related to bladder, prostate, and kidney cancers. Dr. Tawagi explores the clinical implications of circulating tumor DNA (CT DNA), discusses evolving bladder preservation strategies, and addresses the expanding role of PARP inhibitors in prostate cancer. She also emphasizes the importance of equitable access to new therapies and multidisciplinary collaboration in cancer care.

Episode Highlights:

Advances in Bladder Cancer Management

Dr. Tawagi reviews the Niagara study, which integrates dervalumab immunotherapy with standard cisplatin-based chemotherapy. This new regimen has become a standard of care for cisplatin-eligible patients with muscle-invasive bladder cancer. She also discusses ongoing trials and the promise of bladder preservation, especially for patients concerned about quality of life post-cystectomy.

The Power of CT DNA in Personalizing Treatment

CT DNA is emerging as a powerful prognostic tool in bladder cancer, with potential use in escalating or de-escalating treatments based on molecular response. Dr. Tawagi discusses its role in both neoadjuvant and metastatic settings, including trials like the MODERN study.

PARP Inhibitors in Prostate Cancer

For prostate cancer patients with homologous recombination repair mutations—especially BRCA1/2—Dr. Tawagi highlights the role of PARP inhibitors such as niraparib and the Amplitude trial's results in the castration-sensitive setting. She discusses the ongoing debate around sequencing, survival outcomes, and access.

Kidney Cancer and Immunotherapy

An update from the Keynote 564 trial shows continued benefit of adjuvant pembrolizumab for high-risk localized kidney cancer. Dr. Tawagi underscores the importance of patient counseling using risk calculators and timely referral to oncology after nephrectomy.

The Importance of Multidisciplinary Care

Dr. Tawagi emphasizes collaboration among urologists, radiation oncologists, medical oncologists, and other specialties to deliver optimal, patient-centered care. She calls for increased awareness of trial updates and improved access to novel therapies across diverse populations.

Key Takeaway:

Dr. Tawagi emphasizes that the future of genitourinary oncology lies in individualized treatment informed by biomarkers like CT DNA, equitable access to novel therapies, and strong multidisciplinary collaboration to enhance outcomes and preserve quality of life.

Resources:

Website: https://mdnewsline.com/
Newsletter: https://mdnewsline.com/subscribe/
Connect with Dr. Karine Tawagi: Here

In this episode of MD Newsline, Dr. Elias Jabbour, Professor of Medicine at MD Anderson Cancer Center, shares groundbreaking insights into the evolving treatment landscape of chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). He discusses the transformative role of tyrosine kinase inhibitors (TKIs), strategies to achieve treatment-free remission, and how genetic testing, CAR-T therapy, and monoclonal antibodies are reshaping frontline and relapsed leukemia management.

Episode Highlights:

The TKI Revolution in CML

Dr. Jabbour recounts how TKIs have shifted CML from a fatal disease to one with normal life expectancy, even allowing for treatment discontinuation in select patients after prolonged deep molecular remission. He explains how monitoring and response milestones guide therapy and when mutation testing is necessary.

Understanding Resistance and Personalized Care

Resistance to TKIs is rare when patients are compliant. Dr. Jabbour outlines how NGS is used to detect kinase domain mutations and guide next-line therapy, particularly in BCR-ABL-independent resistance. He also shares why genomic profiling isn't yet used for frontline CML treatment but may become more relevant in advanced disease.

Integrating Immunotherapy in ALL

In adult ALL, Dr. Jabbour explains how immunotherapy and TKIs are reducing the need for chemotherapy and transplantation, improving both survival and quality of life. He discusses how CAR-T therapy may move to the frontline setting to shorten treatment duration and potentially eliminate the need for allogeneic transplant.

AML: Moving Toward Targeted Frontline Therapy

Dr. Jabbour outlines how FLT3, IDH, and menin inhibitors are improving outcomes in AML, especially when combined with hypomethylating agents and venetoclax. He stresses the importance of minimal residual disease (MRD) monitoring to tailor therapy and reduce overtreatment.

Overcoming Barriers and Promoting Access

He reflects on challenges like drug cost, limited access to specialized care, and clinical trial barriers such as travel and housing. Dr. Jabbour calls for simplified regimens that can be delivered anywhere, so that all patients—not just those at top centers—can benefit from the latest innovations.

Key Takeaway:

With the right combinations of targeted therapies, immunotherapies, and patient-specific monitoring, many leukemias—especially CML and ALL—are becoming manageable or even curable. But equitable access, affordability, and ongoing collaboration are essential to truly transform care worldwide.

Resources:

Website: https://mdnewsline.com
Newsletter: https://mdnewsline.com/subscribe
Connect with Dr. Elias Jabbour: MD Anderson Profile

In this episode of MD Newsline, Dr. Diego Marzese, a breast cancer researcher specializing in epigenetics, explores how gene expression changes impact tumor behavior, treatment response, and disease progression. He discusses groundbreaking findings on how tumors activate or deactivate genetic alterations at different stages, the role of ethnicity in epigenetic variations, and how AI and machine learning are accelerating cancer research. Dr. Marzese also highlights the shift toward population-based health recommendations and the future of truly personalized cancer treatment.

Episode Highlights:

The Role of Epigenetics in Breast Cancer

Epigenetics refers to how environmental and lifestyle factors influence gene expression without altering DNA sequences. Dr. Marzese's research focuses on how tumors evolve over time, particularly in triple-negative breast cancer and ductal carcinoma in situ (DCIS). By identifying key epigenetic markers, researchers can predict which pre-cancerous conditions may progress to invasive cancer, enabling earlier and more precise treatment strategies.

Ethnicity and Tumor Behavior

Dr. Marzese's recent study found significant epigenetic differences across ethnic groups, particularly in young African American women with breast cancer. These patients exhibited unique hormone-related and muscle development pathway alterations, which may explain their poorer treatment response and higher disease aggressiveness. These findings emphasize the need for ethnicity-specific health recommendations and a more tailored approach to cancer prevention and treatment.

AI and the Future of Personalized Medicine

With the rise of AI and big data analysis, oncology research is progressing faster than ever. Scientists can now rapidly analyze entire genomes, identifying patient-specific treatment strategies that were once impossible. Dr. Marzese envisions a future where cancer treatment is no longer based on broad subtypes but tailored to each patient's unique genetic and epigenetic profile. However, he stresses that education for healthcare providers is crucial to integrating these advances into clinical practice.

Key Takeaway:

Epigenetics is reshaping breast cancer treatment by revealing how tumors evolve and respond to therapy. AI and personalized medicine are paving the way for patient-specific, ethnicity-informed treatment strategies.

Resources & Links:

Website: MD Newsline Newsletter: Subscribe Here

In this episode of MD Newsline, Dr. Ashley Sumrall, a physician specializing in neuro-oncology, explores the challenges and innovations in the field of brain tumor research and treatment. She discusses disparities in care, the role of tumor profiling in personalized medicine, and the impact of AI on imaging and diagnostics. Dr. Sumrall also highlights the devastating effects of drug shortages, the importance of advocacy in cancer treatment access, and how environmental factors may influence rising cancer rates.

Episode Highlights:

Understanding Brain Tumors and Personalized Medicine

Despite decades of research, survival rates for certain brain tumors, including glioblastoma, remain unchanged. However, recent advances in tumor profiling have revealed that not all brain tumors behave the same way, allowing for more targeted treatment approaches. Dr. Sumrall emphasizes the need to expand tumor sequencing efforts to uncover mutations, fusions, and alterations that could impact treatment decisions.

The Role of AI and Technology in Neuro-Oncology

Artificial intelligence is already transforming neuro-radiology, improving MRI scan efficiency by 40% and enhancing blood flow imaging in the brain. AI also holds promise in predicting patient outcomes and treatment responses, but more research is needed to fully integrate these tools into clinical practice.

Drug Shortages and the Fight for Better Access

Drug shortages, particularly of low-cost but essential chemotherapy drugs, have become a major crisis in oncology. While expensive treatments remain widely available, lifesaving medications for children and adults with curable cancers are in short supply. Advocacy efforts at the federal and grassroots levels are crucial in pushing for policy changes that incentivize domestic drug production and improve distribution networks.

Environmental Factors and Rising Cancer Trends

Dr. Sumrall also touches on the emerging research into environmental contributors to cancer, including microplastics, pollution, and potential carcinogens. She highlights a growing trend of increasing colorectal and gastrointestinal cancers in young adults, which remains poorly understood and demands further investigation.

Key Takeaway:

Advances in tumor profiling and AI are transforming neuro-oncology, enabling more personalized treatment approaches. Drug shortages remain a critical issue, limiting access to essential cancer therapies. Increased advocacy and research funding are vital to improving patient outcomes and closing gaps in brain cancer care.

Resources & Links:

Website: MD Newsline Newsletter: Subscribe Here

Connect with Dr. Ashley Sumrall: Atrium Health ASCO (American Society of Clinical Oncology)

In this episode of MD Newsline, Dr. Oluwakemi Onajin, a board-certified dermatologist and dermatopathologist at the University of Chicago, discusses hidradenitis suppurativa (HS)—a chronic, inflammatory skin disease that is often misdiagnosed and takes years for patients to receive proper treatment. She explains the underlying causes of HS, the impact of genetics, hormones, and environmental factors, and how the disease progresses over time. Dr. Onajin also highlights the latest treatment options, including biologic therapies, surgical interventions, and laser treatments, as well as the psychosocial challenges that HS patients face.

Episode Highlights:

Delayed Diagnosis and Challenges in HS Care

HS is frequently misdiagnosed as abscesses or cysts, leading many patients to seek care in emergency rooms and urgent care centers for painful, recurring lesions. On average, it takes 7 to 10 years for an HS diagnosis, despite clear diagnostic criteria that clinicians can use to identify the disease earlier. Dr. Onajin emphasizes the need for better awareness among primary care providers and dermatologists to improve early diagnosis and prevent long-term complications.

Understanding HS Severity and Treatment Strategies

HS severity is classified into three stages using the Hurley system, with mild, moderate, and severe disease requiring different treatment approaches. For mild cases, topical antibiotics and short-term systemic antibiotics are often used. Moderate to severe cases require biologic immunomodulators, surgical interventions like deroofing and excision, and in some cases, laser hair removal to reduce follicular occlusion. Dr. Onajin also stresses the importance of pain management strategies, which can vary based on inflammation levels and nerve involvement.

The Future of HS Research and Patient-Centered Care

Despite advances in treatment, there are still gaps in clinical trials and research, particularly for underrepresented populations. Dr. Onajin advocates for more diverse clinical trial participation and multidisciplinary care approaches to address comorbidities such as diabetes, cardiovascular disease, and inflammatory arthritis. She also highlights the psychosocial impact of HS, including its effects on mental health, employment, and relationships, and the need for greater patient support and education.

Key Takeaway:

Hidradenitis suppurativa is a chronic inflammatory skin disease that is often misdiagnosed, delaying treatment for many patients. Early diagnosis and a personalized approach, including biologics, surgery, and laser therapy, can significantly improve outcomes. Managing comorbidities like diabetes and cardiovascular disease is crucial for overall health. Increased awareness, research, and multidisciplinary care are essential to advancing HS treatment and patient support.

Resources & Links:

Website: MD Newsline Newsletter: Subscribe Here

Connect with Dr. Oluwakemi Onajin: University of Chicago Dermatology